Physician profile
Julia Chan
NPI 1972856649
$11,492.31
in general payments reported to CMS, 2019-2025
21 companies · $1,788 in 2025
The $1,788 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,684 · 2020: $672 · 2021: $1,029 · 2022: $1,525 · 2023: $1,687 · 2024: $3,107 · 2025: $1,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,581.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,089.94 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $1,799.18 | 2019-2025 | Cequa, Xelpros |
| Johnson & Johnson Vision Care, INC. | $1,104.73 | 2019-2025 | Acuvue |
| Allergan, INC. | $1,038.12 | 2019-2022 | |
| Oyster Point Pharma, INC. | $984.56 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $920.14 | 2021-2025 | Clareon Panoptix Pro, Rocklatan, Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $652.31 | 2019-2021 | |
| Harrow Eye, LLC | $402.69 | 2024-2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $393.88 | 2021-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Amgen INC. | $375.54 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $351.07 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $276.59 | 2019 | |
| Abbvie INC. | $243.11 | 2022-2024 | Durysta |
| Dompe US, INC. | $240.02 | 2023-2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $191.64 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $144.84 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $131.88 | 2025 | Xdemvy |
| Glaukos Corporation | $70.25 | 2019-2022 | |
| Thea Pharma INC. | $49.08 | 2025 | Iyuzeh |
| Ivantis, INC | $20.97 | 2019 | |
| Rxsight INC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.